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Abstract A possible explanation for policy implementation failure is that the
views of the policy’s target groups are insufﬁciently taken into account during
policy development. It has been argued that involving these groups in an interactive
process of policy development could improve this. We analysed a project in which
several target populations participated in workshops aimed to optimise the utilisa-
tion of an expensive novel drug (interferon beta) for patients with Multiple
Sclerosis. All participants seemed to agree on the appropriateness of establishing a
central registry of Multiple Sclerosis patients and developing guidelines. Never-
theless, these policy measures were not implemented. Possible explanations include
(1) the subject no longer had high priority when the costs appeared lower than
expected, (2) the organisers had paid insufﬁcient attention to the perceived problems
of parties involved, and (3) changes within the socio-political context. The work-
shops in which representatives of the policy’s target populations participated did not
provide enough interactivity to prevent policy implementation failure.
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There are numerous examples of health policy measures that have failed in their
implementation. A review from the Netherlands Court of Audit indicated that no
evidence of a full policy implementation can be found in previous audits [20]. For
example, the applied measures for reducing greenhouse gas emissions have not met
pre-determined targets, the legal rules for maintaining food safety have not been
able to prevent targeted risks, and policy measures for cost control of medicines
have not resulted in more structural cost control [19].
The theory of argumentative policy analysis offers a possible explanation for
such policy implementation failures [8, 15]. The basic idea of this theory is that
actors’ behaviours can be explained by different views on a problem and the
argumentation behind these views. According to the argumentative approach to
policy analysis [7, 8], action is driven by processes of problem setting [27] in which
actors deﬁne coherent sets of problems and solutions that correspond to these actors’
normative and empirical background theories. The way in which problems are
deﬁned depends on the assumptions the actors make about the situation and their
beliefs regarding what is good practice (normative values).
Combining these ﬁndings with those of classical implementation theory, Grin
and Van de Graaf [10] have argued that a policy will only be effective if both
implementers and target populations consider the proposed policy measure
meaningful. (Target populations consist of persons who will experience the
consequences of a policy when implemented.) This means that the proposed policy
should (a) make sense in the light of problems perceived by the target populations
and (b) be consistent with their normative and empirical background theories.
However, the fact that policy problems and associated solutions tend to shift over
time, different actors with different background theories being involved successively,
renders this rather complicated. In other words, a policy measure is not invented at a
speciﬁc moment in time, but develops over time. Nevertheless, the challenge is to
identify policy measures that cohere with the views of all actors involved.
If the argumentative policy theory is correct, then it is advisable to identify the
policy’s target populations and involve them in the process of policy development.
An interactive process of policy making could thus ensure that policy coheres with
and prevent that it diverges from the views of target groups.
The objective of this paper is to analyse a speciﬁc instance where target
populations were involved in the process of policy development. The policy
institution in this example was the Health Care Insurance Board in the Netherlands
(HCIB). It is an advisory board to the Ministry of Health, particularly with respect to
coverage and reimbursement issues. The Department of Policy Analysis of
Medicines (PAM) is responsible for identifying developments that may jeopardise
optimal medical care, analysing the nature and size of such threats and conducting
further research that may provide a basis for policy decisions. The annual work
programme in which topics are prioritised is submitted to the Ministry of Health for
approval.
The policy objective discussed in this paper was to promote the appropriate use
of a recently introduced drug for patients with multiple sclerosis. Multiple Sclerosis
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123(MS) is a neurodegenerative disease characterised by neurological dysfunction. The
drug interferon-beta (IFNb) appeared to be a promising treatment. However, its
costs were high (€ 12,000 per patient annually) and the evidence of its long-term
effectiveness was limited. Therefore, policy measures to guide the prescription of
this medicine were considered necessary. Representatives of prescribing physicians
(neurologists), health insurance companies, and patients were invited to participate
in two workshops. During these workshops, participants discussed policy measures
that could promote the appropriate use of the new drug. Although two concrete
policy measures had been proposed, these have never been implemented.
In this paper we evaluated whether the theory of the argumentative policy
analysis could explain the proceedings in this case study. It offers a description of
the process of the policy development that included the two workshops, as well as
an analysis of the views of policy makers and target populations in order to assess
whether the proposed policy measures ﬁtted the perceived problems and underlying
background theories.
Methods
Relevant documents were analysed and semi-structured interviews were held with the
various stakeholders. These documents included correspondence, reports from the
Board, internal memos on this subject, a report from Health Council on interferon-
beta, reports from meetings, research proposals, and research reports. Interviews were
held with three HCIB employees, two employees from the Ministry of Health, the
organisers of the workshops, two neurologists, a patient, and a medical advisor from a
health insurance company. Participants of the workshops were contacted and
interviewed to reconstruct the proceedings of the workshops. MS patients were
contacted via a Dutch MS patient organisation. Representatives of target populations
were interviewed to assess their problem deﬁnitions and underlying argumentation.
Interviews were transcribed verbatim. A summary from the interview and a
concept report were sent to respondents for veriﬁcation and literature was used to
check the ﬁndings from interviews or documents. In line with the theory of
argumentative policy analysis, we used the method of reconstructing interpretative
frames to analyse target populations’ argumentation [10, 11, 18]. The idea is to
reconstruct (1) how problems are deﬁned, (2) how solutions or policy measures are
judged, (3) what theoretical and normative assumptions shaped them, and (4) what
normative preferences underlie this all. Together, these four ‘layers’ of evaluation
entail an individual’s interpretative frame.
Results
Proceedings of Project
The content of the workshops was, to a large extent, determined by two reports
concerning IFNb. These had been issued by the HCIB and by the Health Council,
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advice regarding the introduction of IFNb on the Dutch market. The Ministry asked
for recommendations with respect to whether or not restrictions could be imposed
on the reimbursement of the drug.
In May 1996, a committee from the Health Council reported to the Ministry of
Health [9]. This committee was comprised of three neurologists, a chemical
technologist, and a HCIB staff member. It concluded that IFNb could be a
promising new drug, but also cautioned against unrealistic expectations. Clinical
trials had shown that IFNb could decrease the rate and severity of exacerbations, but
there was no evidence of IFNb preventing the onset of disability. The Health
Council emphasised that the drug should be prescribed only to patients who meet
eligibility criteria for the trials. These criteria were: (a) clinically deﬁnite Relapsing
Remitting MS; (b) at least two exacerbations in the two previous years; (c) mild to
moderate disability; and (d) age of 18 years or older. The Council also proposed the
following policy measures: (1) develop a guideline for treatment of MS patients
with IFNb; (2) ensure that the drug is prescribed by neurologists who have sufﬁcient
experience with the diagnosis and treatment of MS patients; (3) properly instruct
and guide MS patients; (4) conduct a systematic follow up of patients using IFNb in
order to evaluate side effects; (5) provide clear indications on which patients should
be treated with IFNb; (6) establish a national registry of MS patients in order to
conduct further research on the effectiveness of IFNb; and (7) conduct a re-appraisal
after a number of years.
June 1996, the HCIB issued recommendations that corresponded partially with
the Health Council’s report [30]. The HCIB recommended that: (a) patients fulﬁl the
criteria described in the Health Council’s report; (b) a treatment protocol be
developed; (c) health insurers approve reimbursement requests before starting
treatment; (d) a prospective registration be established; and (e) the use of IFNb be
re-assessed after 3 years. Restricting prescription to a limited number of experi-
enced neurologists was considered impossible, because IFNb had already been
included in health care packages.
In 1999, the department of Policy Analysis of Medicines (PAM) started a project
on IFNb. Initially it they considered evaluating other, less expensive interventions
that could be effective, but are of no interest to the industry. Indications had been
received from the ﬁeld that a much cheaper drug, namely methotrexate (used in
oncology and rheumatoid arthritis), could be as effective as interferon. Furthermore,
PAM considered developing a national database of MS patients. PAM later decided
that conducting a clinical trial was not its responsibility. PAM staff, in collabora-
tion with neurologists, decided to initiate the development of a treatment protocol
and a national registry of MS patients. They proposed the organisation of two
workshops.
Workshops
In 2000, these workshops were organised by an external institute for policy
research. The ﬁrst workshop aimed to provide an overview of the criteria that are
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amongst health insurance companies into current reimbursement practices with
respect to IFNb. This inventory study was performed by a HCIB department. The
results from the inventory study on current reimbursement practices indicated
that health insurance companies did not assess reimbursement requests against
medical content. Assessments were limited to an administrative review of the
completeness of data [4]. Nevertheless, health insurance companies considered
the pre-utilisation approval effective, because it functioned as an administrative
barrier. The authors of this report recommended the following: (a) assess whether
a pre-utilisation approval by a central committee could improve the assessment
of reimbursement requests; (b) develop a clear protocol and design application
forms.
Neurologists, medical advisors from health insurance companies, policy makers,
and a representative from a patient organisation participated in the workshop.
During the workshop, vignettes with patient descriptions were used to discuss which
patients should be treated with IFNb. The organisers concluded that only a few
problems were perceived with respect to criteria for IFNb use. Health insurers
questioned whether the situation was indeed problematic given the small size of the
patient population and IFNb’s status as an essential medicine. Neurologists argued
that problems arose incidentally. Most often, these problems were related to
reimbursement requests for continued use of IFNb. All participants agreed that
subjectivity in decisions on prescription should be minimised. The participants
claimed that clear distinctions should be made between the criteria for initialising
treatment and the criteria for continuing treatment. The development of a guideline
by neurologists was considered relevant. According to the participants, small
adjustments of the current criteria would be sufﬁcient [2].
The second workshop aimed to obtain advice on how existing databases could
be improved so that the effects of IFNb or other new drugs for MS patients could
be evaluated. In preparation for this workshop, a neurologist was asked to make an
inventory of available databases that contained data on IFNb users. This inventory
showed that data on MS patients were no longer being collected systematically in
the Netherlands [2]. Former local databases were no longer up-to-date. The
participants in the workshops agreed that a national database could be relevant and
could serve the following goals: (a) policy making (such as ﬁnancial surveys,
planning health care capacity); (b) research (effects of treatment; monitoring for
side effects); and (c) clinical practice support for neurologists (reﬂection on
clinical practice, improvement of expertise). Participants agreed on the inclusion of
general static data in the database, such as demographic details, diagnosis (type
MS), the criteria used to make the diagnosis, and the initial treatment. Participants
disagreed on the kinds of dynamic data, such as treatment details and information
on physical functioning. A database including a broad range of data could be
useful for research, but this was considered expensive. A small database that
includes static data only could be used as a sample frame for selecting potential
participants in further studies. In their report, the organisers concluded that
additional research was needed to ascertain which variables should be included in
the database.
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Based on the organisers’ report, the HCIB proposed the following policy measures
to the Ministry of Health [5]:
• Have neurologists develop an evidence-based guideline for the treatment of
patients with multiple sclerosis.
• Have reimbursement requests for IFNb appraised on medical grounds. Possibly,
implement a central pre-utilisation approval by experts (neurologists).
• Deﬁne clear criteria for (dis)continuing IFNb reimbursement.
• Establish a national registry of MS patients. The database should enable
scientiﬁc research, the improvement of treatments, monitoring, and the evalu-
ation of efﬁciency and therapeutic value of new interventions.
In 2003, a medical advisor from a health insurance company mentioned that
some small changes had been made to the procedures established for judging
reimbursement requests (requests for continued use). A neurologist mentioned
working on a guideline for diagnosis and treatment of MS patients. According to a
PAM staff member, neither a central pre-utilisation approval nor a national database
to prospectively register patient data had been established.
Reconstructed Interpretative Frames
In June 2003, we conducted interviews to reconstruct interpretative frames of policy
makers and policy’s target populations. The actors’ views are summarised in
Table 1 (IFNb guideline) and Table 2 (national database).
Ministry of Health
Initially, the Ministry contended that the long-term effectiveness of the drug was not
established sufﬁciently, while the acquisition costs were high. Trials had shown that
IFNb decreased the number of exacerbations, but it was unknown whether IFNb
would prevent disability. The potential target population, namely patients with MS,
is large and the expectations of both patients and physicians may also have been
high. As a result, the risk that the drug could be used inaccurately was considered to
be high. Consequently, additional policy measures to control IFNb use in clinical
practice were requested.
According to employees from the Ministry of Health, the HCIB report [5] had
revealed that only health insurers perceived few problems with respect to judging
reimbursement requests. The costs of a committee for a central pre-utilisation
approval were considered relatively high, while the costs of the interferon-beta
prescription were less than expected, namely €18 million (in 1999) versus the
€90-180 million estimated by the Ministry. Therefore, both interventions were
considered to be no longer relevant.
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123PAM Staff
According to the PAM staff, the main problem was that the use of IFNb was
expected to extend to other subgroups of patients. A central pre-utilisation approval
in combination with a national registry of MS patients could provide a solution. This
contention was made because the situation concerning IFNb resembled the situation
concerning other drugs for which a central pre-utilisation approval had already been
established. In that case, requests for reimbursement of drug use were judged by a
central committee of medical experts. For this purpose, a clear protocol including
criteria for IFNb use is needed. Simultaneously, patient data were recorded in a
national registry.
At the time that PAM staff started their project, it was undesirable to evaluate
why the proposed policy measures had not been implemented until then. Reason
was a change in the relationship between the HCIB and the Ministry of Health.
In 1999, the HCIB, an independent advisory board, was established as the successor
to the Sickness Funds, which was a politically involved advisory board comprised of
actors from the ﬁeld.
After completion of the project, the PAM staff considered the option of having
reimbursement requests judged by a central committee no longer meaningful. They
considered the implementation of policy measures difﬁcult because the drug had
already been introduced several years earlier. Limiting or discontinuing the
reimbursement of IFNb would have been practically impossible. Furthermore, the
scale of problems relating to the prescription and/or reimbursement of IFNb and
the costs related to IFNb use turned out to be much smaller than expected. PAM
considered the initiation of a national MS patient registry without the central pre-
utilisation judgment to be unfeasible.
Medical Advisor Health Insurance Company
According to a medical advisor from a health insurance company, the problem was
attributable to a lack of clarity on exactly what kind of patients beneﬁt from IFNb.
IFNb is an expensive drug and the costs are either carried by the community (public
health insurance) or reimbursed on an individual basis (private health insurance).
Preferably, physicians should develop a guideline on the relative position of IFNb in
relation to alternative interventions. At the time of IFNb’s introduction, a central
pre-utilisation approval could have been relevant. However, time had passed and the
prescription of IFNb had become common practice. Unfortunately, new drugs are
often introduced and included in the health care package long before all medical
specialists agree on criteria for treatment. Professionals cannot develop guidelines
quickly. In contrast, the time that passes between a drug being introduced into
the market and its inclusion in the health care package is regulated by law and,
in most cases, quite short. As a temporary solution, the drug could be included into
the health care package under certain conditions, such as the registration of patient
data.
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A neurologist mentioned working on a guideline for diagnosing and treating MS
patients as part of an initiative from the Dutch Society for Neurology. A guideline
for diagnosis and treatment was considered relevant as it could support evidence-
based practice. As in other medical ﬁelds, knowledge and treatment options have
increased. The development of a guideline is a time-consuming endeavour as, often,
it has to be done alongside the professional’s usual activities. A central pre-
utilisation approval was no longer relevant. Prescribing IFNb was considered
common practice, also in small general hospitals. Most neurologists were already
familiar with the indications for treatment. IFNb was proven to be effective in one
type of MS that is characterised by invalidating exacerbations (relapsing remitting
MS) through clinical trials that demonstrated IFNb’s ability to decrease the severity
and frequency of these exacerbations. A national database could still be useful.
However, its purpose must be clear. An appropriate goal could be to evaluate the
long-term effectiveness of IFNb. The neurologist questioned whether participants
would have come to agreement on speciﬁc recommendations, such as which data
should be collected and who should become the owner of the database. Most
neurologists do have ‘‘their own kingdoms’’ and do not want to share these with
others.
Patient
The patient claimed that agreement amongst neurologists about MS treatment could
be useful. For him, the main problem was that MS care differs between hospitals.
He conveyed his experiences with receiving contradictory answers to questions
from numerous health professionals and the option of using IFNb had not been
discussed in the hospital where he was initially treated. For this patient, the
exacerbations are highly invalidating. Obviously, his preference is to lead a normal
life, in so far as that is possible. MS has a high impact on his life.
Discussion
Although results from the workshops showed that all respondents agreed that
developing a guideline and a national database could be meaningful, these policy
measures have never been implemented. A number of factors can provide an
explanation for the proceedings in this project.
Firstly, the costs of IFNb appeared to be lower than expected. Perhaps the
information campaign on IFNb had had this effect [3]. It may also have been that
the calculation by the Ministry of Health, which differed from calculations made by
the Health Council and rested on the assumption that all MS patients are treated
with IFNb, were unrealistic. In any case, the subject of IFNb no longer had high
priority. From the point of view of policy makers, the expected high costs of IFNb
in combination with its uncertain effectiveness were the main problems behind the
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still higher priority than the limited knowledge on IFNb’s effectiveness. As a result,
policy makers left it to the medical profession to implement policy measures.
Neurologists, however, considered cost-containment not their problem and not their
responsibility.
This also explains why the initial questions about the long-term effectiveness
remained unanswered, without this being perceived as a problem. The effectiveness
of IFNb and the possible role of the industry was an issue of international debate.
Clinical trials have shown that IFNb decreased the number and severity of
exacerbations in patients with relapsing-remitting MS [16, 23]. Probably, this is
enough reason for neurologists to claim the right to prescribe IFNb. That evidence
of long-term effectiveness, in terms of preventing disability, and safety was still
limited [26] is not of great concern to them. Neither is the possible inﬂuence of the
industry on prescription practices through the ﬁnancing of clinical trials that had
been discussed [13, 21, 22, 28]. Some authors have even challenged the hypothesis
of MS as an inﬂammatory auto-immune disease [1]. A national registry could have
been relevant from this point of view. In the UK, the Department of Health initially
refused to reimburse IFNb use for reasons of costs [17]. In 2002, however,
agreements were made with the industry concerning the funding of IFNb. The
Department of Health announced that it would reimburse IFNb for MS patients who
agreed to participate in a monitoring program on the effectiveness of IFNb.
Secondly, the policy development process from the beginning centred around two
speciﬁc policy measures, whereas it could have started with a broader scope, actors
involved ﬁrst eliciting the problems they perceive and adequately structuring the
problem. Now, the proposed measures appeared not to be the most optimal solutions
for the problems as perceived by neurologists, and therefore represented right
solutions to the wrong problems. This typically concerns what Hischemuller and
Dunn have coined an ‘error of the third kind’ [6, 14]. We have found that on a ﬁrst
order level, all actors agreed that a national guideline and a registration could be
meaningful. But as it was, on a second order level they disagreed as to what goals
such policy measures should serve. For example, neurologists considered a national
guideline relevant, as long it was a broad guideline on the diagnosis and treatment of
MS in general. All actors agreed that a national registry could be relevant, but deﬁned
different goals. Each goal came with different variables to be included in the registry.
Thirdly, during the workshops, the proposed policy measures remained rather
vague and were not elaborated in detail. As a result, participants could easily
consent without violating their background theories and preferences. They had not
felt the urge to (re)consider these theories and preferences. This, however, was
necessary, as is clearly illustrated by the respondents who questioned whether
participants would have come to agreement on speciﬁc recommendations, such as
which data should be collected and who should become the owner of the registry.
Such an agreement requires that policy measures are made sufﬁciently substantive
for every actor to understand what are the consequences. Moreover, it requires that
background theories and normative preferences are elicited and scrutinised.
Fourthly, changes in the socio-political context affected policy development.
Opinions with respect to which kind of policy measures are the responsibility of the
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to obtain relevant information that would not be provided by the industry.
Simultaneously, their position towards another Dutch institute involved with
subsidising clinical research changed. Putting out clinical trials was then no longer
their responsibility. Furthermore, the relationship between the HCIB and the
Ministry of Health changed over the course of this project. These changes strongly
affected ideas with respect to the Board’s responsibility on initiating a national
registry of patient data. On this basis we conclude that the workshops failed to meet
the objectives set for interactive processes in policy development, namely to prevent
policy implementation problems as a result of diverging views amongst target
groups. Moreover, we concede that they could not have met those objectives. From
the case of IFNb, we infer that an interactive process should meet the following
criteria:
1. The interaction should cover the whole process from problem structuring to
policy implementation, in order to be able to deal with problem shifts and
changes in the socio-political context. It is not enough to reduce interactivity to
workshops at one or two moments in time.
2. Actors involved should resist the temptation to think that policy problems can
be understood at a ﬁrst order level. That is, background theories and normative
preferences should be explicated in the problem deﬁnition phase. Only if
problem structuring is taken seriously in this sense can one think of developing
solutions that could meet with the approval of all target groups.
3. Developing widely endorsed solutions requires that actors involved are willing
to learn from one another and adapt their views if necessary. A process of
interactive policy development should include room for such learning processes
[12, 24, 25, 29]. Grin and Van de Graaf [10] have argued that learning is likely
to occur only if external events urge a revision of background theories and
preferences, or if repeated failures show actors that their background theories
are not functional.
4. Proposed policy measures should be sufﬁciently elaborated, as to enable target
groups to assess their consequences and constructively engage in the interactive
process. As the case of IFNb shows, actors involved are not willing to
reconsider their background theories and preferences, should proposed policy
measures not be sufﬁciently elaborated and actors involved not understand what
is at stake.
In sum, this study has shown that the organisation of workshops in which target
populations participate does not qualify as an appropriate process of interactive
policy development. From the beginning, emphasis had been put on a limited
number of interventions aimed to control the expected increase in treatment costs.
Although target populations participated in policy development, perceived problems
and which interventions could provide a solution had been discussed insufﬁciently.
For policy development to be successful, interactive methods are needed, in which
problem deﬁnitions and assumptions are explicated and discussed, providing an
opportunity for mutual learning between actors involved.
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